Chemoinformaics analysis of 4-(1-cyclopenten-1-yl)-1-morpholino-1-cyclopentene
| Molecular Weight | 219.328 | nRot | 2 |
| Heavy Atom Molecular Weight | 198.16 | nRig | 16 |
| Exact Molecular Weight | 219.162 | nRing | 3 |
| Solubility: LogS | -3.1 | nHRing | 1 |
| Solubility: LogP | 2.8 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 37 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 16 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 21 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 14 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 39.2847 |
| nHD | 0 | BPOL | 24.5133 |
| QED | 0.662 |
| Synth | 3.579 |
| Natural Product Likeliness | 0.035 |
| NR-PPAR-gamma | 0.01 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.973 |
| Pgp-sub | 0.001 |
| HIA | 0.003 |
| CACO-2 | -4.566 |
| MDCK | 0.0000176 |
| BBB | 0.717 |
| PPB | 0.585011 |
| VDSS | 0.946 |
| FU | 0.251922 |
| CYP1A2-inh | 0.159 |
| CYP1A2-sub | 0.262 |
| CYP2c19-inh | 0.662 |
| CYP2c19-sub | 0.832 |
| CYP2c9-inh | 0.239 |
| CYP2c9-sub | 0.387 |
| CYP2d6-inh | 0.057 |
| CYP2d6-sub | 0.854 |
| CYP3a4-inh | 0.222 |
| CYP3a4-sub | 0.433 |
| CL | 9.194 |
| T12 | 0.558 |
| hERG | 0.021 |
| Ames | 0.027 |
| ROA | 0.067 |
| SkinSen | 0.92 |
| Carcinogencity | 0.919 |
| EI | 0.702 |
| Respiratory | 0.754 |
| NR-Aromatase | 0.041 |
| Antiviral | Yes |
| Prediction | 0.880636 |